TBA 354

Drug Profile

TBA 354

Alternative Names: TBA-354

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Global Alliance for TB Drug Development; University of Auckland
  • Developer Global Alliance for TB Drug Development
  • Class Antituberculars; Nitroimidazoles; Oxazines; Pyridines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in USA (PO, Suspension)
  • 19 Nov 2015 Global Alliance for TB Drug Development plans a phase I trial in Healthy volunteers in USA (NCT02606214)
  • 01 Jan 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top